Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.
about
Retreatment with Sofosbuvir/Ledipasvir With or Without Lead-in Interferon-β Injections in Patients Infected with Genotype 1b HCV after Unsuccessful Daclatasvir/Asunaprevir Therapy.Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCVRetreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience.Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature.Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events.The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.
P2860
Q40051404-ED20CEBF-449A-4EAE-BE6F-187B891F1DFFQ40228687-2DBF85CD-63DF-4646-A6F2-4299DECDEA29Q47121490-62BAE606-51E1-4514-98C9-D7070ABD8553Q47560943-C55CDCD1-8A2C-405A-9839-DB838801C52EQ47572297-69F634CA-9565-4FDB-BF1F-053E5B73F20FQ47657221-15B03343-A327-42AC-88E2-BC5321C82019Q49334341-DBE30FC8-2447-4DEB-ACDA-E9B197909AABQ50045992-260AC9B1-3DCF-4EA9-991D-C6937F11DF3CQ53694789-445ED52A-489B-4709-B4B8-17114C456789Q55212538-7B97EB2B-6143-4EF5-B02C-8A55AD7E51AEQ55303958-4049E39F-1A08-48A5-ACFC-282DB630AB98
P2860
Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Clinical evaluation of sofosbu ...... clatasvir/asunaprevir therapy.
@en
type
label
Clinical evaluation of sofosbu ...... clatasvir/asunaprevir therapy.
@en
prefLabel
Clinical evaluation of sofosbu ...... clatasvir/asunaprevir therapy.
@en
P2093
P2860
P356
P1433
P1476
Clinical evaluation of sofosbu ...... clatasvir/asunaprevir therapy.
@en
P2093
Akihito Tsubota
Atsunori Kusakabe
Etsuko Iio
Hiroshi Abe
Kayoko Matsunami
Kei Fujiwara
Keizo Kato
Kentaro Matsuura
Koichi Takaguchi
Masanori Atsukawa
P2860
P356
10.1111/HEPR.12898
P577
2017-03-22T00:00:00Z